Imara’s IMR-687 an Orphan Drug in the U.S. for beta-thalassemia

The FDA has granted Orphan Drug Designation for IMARA’s (NASDAQ:IMRA) IMR-687 for the treatment of patients with beta-thalassemia.

Among the benefits of Orphan Drug status in the U.S. is a seven-year period of market exclusivity for the indication, if approved.

https://seekingalpha.com/news/3585722-imaras-imrminus-687-orphan-drug-in-u-s-for-beta-thalassemia